Antares Pharma (ATRS) Enrolls First Patient in QuickShot Safety, Pharmacokinetic Study
Tweet Send to a Friend
Antares Pharma (NASDAQ: ATRS) announced that the first patients have been enrolled in a double-blind, multiple-dose, 26-week safety and pharmacokinetic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
